跳至主要内容
临床试验/CTRI/2018/02/011939
CTRI/2018/02/011939招募中不适用

A PROSPECTIVE, COMPARATIVE, RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SNEC30 (CURCUMA LONGA) IN THE TREATMENT OF ORAL SUBMUCOSAL FIBROSIS

Arbro Pharmaceuticals Pvt Ltd1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2017年11月27日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
80
试验地点
1
主要终点
Reduction in burning sensation.

研究概览

简要总结

The aim of the present study is to conduct study to evaluate its utility in oral submucosal fibrosis where there is a reasonable probability ofcurcuminoids being useful / curative.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • 1.Patient or his legally accepted representative is willing to give informed consent.
  • 2.Patient is in the age range of 18-65 yrs.
  • 3.Patient clinically diagnosed with OSF (diagnosed on the basis of reduction in interincisal distance on maximum mouth opening and palpable fibrous bands involving oral mucosa).
  • 4.Patient is willing to discontinue the use of tobacco in any form or areca 1-month prior to the commencement of the treatment.

排除标准

  • 未提供

结局指标

主要结局

Reduction in burning sensation.

时间窗: reduction in burning sensation and mouth opening will be checked at enrollment day , day 28, day 56 and day 84.

Improvement in mouth opening.

时间窗: reduction in burning sensation and mouth opening will be checked at enrollment day , day 28, day 56 and day 84.

次要结局

  • Safety and tolerability of the drug will be evaluated on the basis of occurrence / non-occurrence, type, frequency and duration of drug-related adverse reactions(Safety and tolerability of the drug will be evaluated throughout the study.)

研究者

发起方
Arbro Pharmaceuticals Pvt Ltd
申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验